Skip to main content
. Author manuscript; available in PMC: 2013 May 19.
Published in final edited form as: J Cogn Neurosci. 2012 May 9;24(8):1709–1724. doi: 10.1162/jocn_a_00241

Table 1.

Sample Characteristics

All Patients ICB Subgroups
ICB No ICB p-value
Sample Size 38 19 19
Age (yrs) 62.1 (7.0) 60.9 (5.6) 63.2 (8.1) >.10
Gender (M:F) 19:19 10:9 9:10 >.10
Education (yrs) 16.6 (2.6) 16.8 (2.3) 16.4 (2.9) >.10
MMSE 28.8 (1.5) 28.8 (1.5) 28.8 (1.5) >.10
Disease Duration (yrs) 7.6 (5.9) 9.4 (6.8) 5.9 (4.3) .06
UPDRS Motor Score 16.8 (8.1) 18.4 (7.4) 15.3 (8.6) >.10
Agonist LEDD (mg) 247 (138) 277 (145) 218 (128) >.10
Agonist Duration (yrs) 3.7 (3.6) 4.6 (4.0) 2.8 (2.9) >.10
Daily Levodopa (mg) -- 584 (270)
(n = 13)
618 (220)
(n = 10)
>.10

MMSE = Mini-Mental Status Exam; UPDRS = Unified Parkinson’s Disease Rating Scale; LEDD = Levodopa Equivalent Daily Dosage (in mg); ICB = Impulse-Compulsive Behaviors